GLP-1s and NAION: Do Patients Need a Warning?
Medscape Medical News reports on federal litigation alleging GLP-1 drugs are linked to NAION, a rare optic nerve condition. European regulators list it as a very rare potential effect of semaglutide; US labels do not. The NAION case group grew to 247 cases from 29 in January. Ophthalmology groups call research findings mixed, and drugmakers say causation has not been established.
Why it matters: Relevant to Maryland adults weighing semaglutide or tirzepatide for medical weight loss, and to the prescribers and ophthalmologists who discuss these drugs with them.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to medscape.com. October 6, 2026.